Oct 8, 2026 · 6 min

European stocks split between buybacks and obesity-drug doubts

Tesco Climbs, Imperial Brands Rises, Zealand Pharma Slips

The episode shows how shareholder returns can lift established companies while uncertain drug economics quickly punish growth expectations.

3 key takeaways

1Tesco’s strong first-half results, online sales and expanded buyback drive its shares higher.
2Imperial Brands gains after announcing a £1.5 billion buyback and reaffirming its outlook.
3Zealand Pharma falls as trial concerns, discontinuations and obesity-drug pricing pressure reshape expectations.

Don't miss

Zealand Pharma’s decline illustrates how trial results, treatment discontinuation and pricing pressure can quickly undermine obesity-drug expectations.

The brief

European equities open the report: Tesco rises after strong first-half results, better online sales and cost control support an expanded share-buyback plan.

Imperial Brands also gains, with a £1.5 billion buyback for the next fiscal year reinforcing investor confidence alongside its cost-cutting efforts.

Zealand Pharma moves the other way after KBC downgrades the stock, citing disappointing trial results, high discontinuation rates and pricing pressure in obesity drugs.

The episode then shifts from markets to urbanization, asking how technology and artificial intelligence can help cities absorb rapid population growth.

Dubai provides the case study: long-term planning and technology are presented as tools for turning demographic change into a managed growth strategy.

What was said on this episode

7 statements · 5 positive · 2 negative

Tiwa Adebayoon Tesco sharesPositive0:44
Tesco shares rose as much as 3.3% after positive results and forecasts
“their shares are up by as much as about 3.3%”
Listen at 0:44
Tiwa Adebayoon Imperial BrandsNegative2:49
Imperial Brands faces declining smoking and mounting regulatory challenges
“Imperial Brands really grappling with the decline that we're seeing in smoking and also mounting regulatory challenges”
Listen at 2:49
Tiwa Adebayoon PetrelatideNegative3:33
Petrelatide trial results were unfavorable and showed high discontinuation rates
“Petrelatide, had trial results which haven't been super positive, showing high discontinuation rates”
Listen at 3:33
Stephen Carrollon AI in smart citiesPositive4:42
AI will compress processes and increase speed in smart-city applications
“AI will allow in the smart city space to compress a lot of things. The speed will change.”
Listen at 4:42
Rohit Kumaron DubaiPositive5:02
Dubai learned substantially from its sudden population increase
“I think Dubai has learned a lot from a sudden increase in population”
Listen at 5:02
Rohit Kumaron DubaiPositive5:08
Dubai responded very effectively to its sudden population increase
“I think they reacted very well to it”
Listen at 5:08
Rohit Kumaron Dubai urban planningPositive5:10
Dubai has a long-term urban-planning vision
“They have a long-term urban planning vision”
Listen at 5:10

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.